<SEC-DOCUMENT>0001193125-17-266085.txt : 20170824
<SEC-HEADER>0001193125-17-266085.hdr.sgml : 20170824
<ACCEPTANCE-DATETIME>20170824080105
ACCESSION NUMBER:		0001193125-17-266085
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170822
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170824
DATE AS OF CHANGE:		20170824

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAPTYSBIO INC
		CENTRAL INDEX KEY:			0001370053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203828755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37985
		FILM NUMBER:		171048212

	BUSINESS ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-362-6295

	MAIL ADDRESS:	
		STREET 1:		10421 PACIFIC CENTER COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANAPTYS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20060724
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d445468d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report: August&nbsp;22, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Date of earliest event reported) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO,
INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other
Jurisdiction of Incorporation) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-37985</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">20-3828755</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>10421 Pacific Center Court, Suite 200</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>92121</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">362-6295</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election Of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Effective on August&nbsp;22, 2017, the Board of Directors (the
&#147;<B><I>Board</I></B>&#148;) of AnaptysBio, Inc. (&#147;<B><I>AnaptysBio</I></B>&#148;) elected J.&nbsp;Anthony Ware, M.D. to fill a vacancy on the Board as a Class&nbsp;II director. Dr.&nbsp;Ware shall hold office for a term expiring at the
2019 Annual Meeting of AnaptysBio&#146;s stockholders, which is the next stockholder meeting at which Class&nbsp;II directors will be elected. There is no arrangement or understanding between Dr.&nbsp;Ware and any other persons pursuant to which
Dr.&nbsp;Ware was selected as a director. Dr.&nbsp;Ware is not a party to and does not have any direct or indirect material interest in any transaction with AnaptysBio required to be disclosed under Item 404(a) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> The Board determined that Dr.&nbsp;Ware qualifies as an independent director pursuant to the Securities Act of 1933 and the listing standards of the NASDAQ Stock Market, in each case as currently in effect.
Dr.&nbsp;Ware also will enter into AnaptysBio&#146;s standard form of indemnity agreement for its directors and executive officers, which was filed as Exhibit&nbsp;10.01 to AnaptysBio&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1,</FONT> as filed with the Securities and Exchange Commission on September&nbsp;9, 2015. The indemnification agreement will be effective as of the date of his appointment to the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Ware will be compensated in accordance with the standard <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, including
an annual cash retainer, an initial option grant, and an annual option grant. Dr.&nbsp;Ware will receive a pro rated annual grant and a pro rated annual cash retainer for the portion of 2017 that he will serve as a director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.01</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release issued by AnaptysBio dated August&nbsp;24, 2017.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AnaptysBio, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: August&nbsp;24, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic Piscitelli</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dominic Piscitelli</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman">Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.01</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release issued by AnaptysBio dated August&nbsp;24, 2017.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.01
<SEQUENCE>2
<FILENAME>d445468dex9901.htm
<DESCRIPTION>EX-99.01
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.01</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.01 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g445468g0823204612276.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANAPTYSBIO ANNOUNCES APPOINTMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>J. ANTHONY WARE, M.D. TO BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO</B>, August&nbsp;24<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 2017 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage
biotechnology company developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody product candidates focused on unmet medical needs in inflammation, today announced the appointment of J. Anthony
Ware, M.D. to its board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to welcome Dr.&nbsp;Ware to AnaptysBio&#146;s board of directors,&#148; said Hamza Suria,
president and chief executive officer of AnaptysBio. &#147;Dr.&nbsp;Ware&#146;s experience in the clinical development and regulatory approval of novel immune-modulatory therapeutics will be a key resource for AnaptysBio as we advance our
wholly-owned inflammation-focused antibody pipeline.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Ware said, &#147;I am pleased and honored to join AnaptysBio&#146;s Board of
Directors. The Company has a very interesting clinical-stage pipeline focused on the treatment of severe inflammatory diseases with unmet medical need. I look forward to working with AnaptysBio&#146;s management team to advance the development and
regulatory approval of ANB020 and ANB019.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Ware currently serves as the senior vice president of product development of Lilly <FONT
STYLE="white-space:nowrap">Bio-Medicines</FONT> at Eli Lilly and Company, where he is responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.&nbsp;His sixteen year tenure at Eli Lilly has
included the clinical development, regulatory approval and launch of numerous novel therapeutics, including Taltz<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Olumiant<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Cymbalta<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Cialis<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Effient<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and
Trulicity<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>.&nbsp;Prior to Eli Lilly, Dr.&nbsp;Ware served as professor of medicine and molecular pharmacology at Albert Einstein College of Medicine in New York, where he was also chief of
cardiology at Montefiore Medical Center.&nbsp;Before then, Dr.&nbsp;Ware was on the faculty of Harvard Medical School and also served as a senior physician and director of the coronary care unit at Beth Israel Hospital.&nbsp;Dr.&nbsp;Ware received a
bachelor of science degree from Washburn University, a medical degree from the University of Kansas, has served in internships at the University of Texas at Houston and Baylor College of Medicine, and is board certified both in internal medicine and
cardiovascular disease. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About AnaptysBio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AnaptysBio is a clinical-stage biotechnology company developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
antibody product candidates focused on unmet medical needs in inflammation. The company&#146;s proprietary anti-inflammatory pipeline includes its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-33</FONT></FONT> antibody
(ANB020) for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-36R</FONT></FONT> antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio
of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of graft-versus-host disease.
AnaptysBio&#146;s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses <I>in vitro</I> SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome
the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antagonist antibody <FONT STYLE="white-space:nowrap">(TSR-042)</FONT> an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-TIM-3</FONT></FONT>
antagonist antibody <FONT STYLE="white-space:nowrap">(TSR-022)</FONT> and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-LAG-3</FONT></FONT> antagonist antibody <FONT STYLE="white-space:nowrap">(TSR-033),</FONT> which are
currently under clinical development with TESARO, and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> checkpoint agonist antibody <FONT STYLE="white-space:nowrap">(CC-90006)</FONT> currently in the clinic
with Celgene. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release contains forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the company&#146;s ability to advance its pipeline and
key resources for such advancement and the company&#146;s ability to advance the development and regulatory approval of ANB020 and ANB019 ; Statements including words such as &#147;plan,&#148; &#147;continue,&#148; &#147;expect,&#148; or
&#147;ongoing&#148; and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause
our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company&#146;s actual activities or results to differ
significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company&#146;s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product
candidates, the timing and results of preclinical and clinical trials, the company&#146;s ability to fund development activities and achieve development goals, the company&#146;s ability to protect intellectual property and other risks and
uncertainties described under the heading &#147;Risk Factors&#148; in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and
the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monique Allaire </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THRUST Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">617.895.9511 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">monique@thrustir.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g445468g0823204612276.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g445468g0823204612276.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y -,# 2(  A$! Q$!_\0
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M:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
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# /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
